Cancer medicine · 2026
Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High-Risk Recurrence Factors: A Phase II Single-Center Prospective Study.
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tian Yitong, Lei Tian, Ruan Qingyang, Zhou Xueying, Shen Ruijing, Xie Tianao, Li Shijie, Cai Xiujun, Chen Mingyu
Аннотация
BACKGROUND: Biliary tract cancer (BTC) is an aggressive malignancy characterized by a high recurrence rate and poor postoperative prognosis, despite advances in adjuvant therapy. This phase II study evaluated the efficacy and safety of a novel adjuvant regimen combining envafolimab, lenvatinib, and capecitabine in patients with BTC at high risk of recurrence following R0 resection.
METHODS: This single-center, open-label, single-arm phase II trial enrolled patients with high-risk recurrence factors after curative resection. Patients received envafolimab (400 mg subcutaneously once every 3 weeks), Lenvatinib (8 mg orally once daily), and capecitabine (1000 mg/m2 orally twice daily, 2 weeks on/1 week off, continued without cycle limitation). The primary endpoint was disease-free survival (DFS); secondary endpoints included overall survival (OS) and safety.
RESULTS: 28 of 30 screened patients were included in the final analysis. The median DFS was 15.63 months, and the 1-year DFS rate was 68.3%. Median OS was not reached but 1-year OS was 91.4%. Treatment-related adverse events (TRAEs) occurred in 17 patients, with grade 3/4 TRAEs observed in eight patients. No treatment-related deaths were reported. Exploratory analysis suggested that baseline CA19-9 levels were significantly associated with early recurrence.
CONCLUSIONS: The adjuvant combination of envafolimab, lenvatinib, and capecitabine demonstrates promising efficacy and a manageable safety profile in high-risk BTC patients after R0 resection. However, these findings still require validation in larger, multicenter, randomized controlled trials.
METHODS: This single-center, open-label, single-arm phase II trial enrolled patients with high-risk recurrence factors after curative resection. Patients received envafolimab (400 mg subcutaneously once every 3 weeks), Lenvatinib (8 mg orally once daily), and capecitabine (1000 mg/m2 orally twice daily, 2 weeks on/1 week off, continued without cycle limitation). The primary endpoint was disease-free survival (DFS); secondary endpoints included overall survival (OS) and safety.
RESULTS: 28 of 30 screened patients were included in the final analysis. The median DFS was 15.63 months, and the 1-year DFS rate was 68.3%. Median OS was not reached but 1-year OS was 91.4%. Treatment-related adverse events (TRAEs) occurred in 17 patients, with grade 3/4 TRAEs observed in eight patients. No treatment-related deaths were reported. Exploratory analysis suggested that baseline CA19-9 levels were significantly associated with early recurrence.
CONCLUSIONS: The adjuvant combination of envafolimab, lenvatinib, and capecitabine demonstrates promising efficacy and a manageable safety profile in high-risk BTC patients after R0 resection. However, these findings still require validation in larger, multicenter, randomized controlled trials.